Pipeline

Discovery
Preclinical
Pre-IND
Phase I
Phase II
CollaboratorsCollab.
ANV419
undisclosed

About

Meet Our Team

We are a dedicated team of scientists with decades of collective experience in drug development.
Our expertise, curiosity and drive to deliver tangible results set us apart.
We focus on science in order to identify solutions to patient needs.

High-profile investors fund Anaveon

Others share our vision, and international investors have backed Anaveon with funding of more than 146 million CHF (€140 million) since the company’s foundation in 2017.

HCP

Message to Health Care Professionals (HCP)

Anaveon – Message to Health Care Professionals (HCP)

We are exploiting the power of cytokines to orchestrate immune responses by using protein engeneering to create safe and effective treatments for patients with high unmet medical needs.

Corporate Positioning & Design, Concept, Webdesign & Code:
Schlatter corporate GmbH
Davidstrasse 45
CH-9000 St.Gallen
schlattercorporate.com
Our website uses cookies to provide you with the best online experience. By using our website, you accept the use of cookies in accordance with our Privacy Policy.
Accept